NBTX · available-data snapshot
Nanobiotix S.A. (NBTX): Available-Data Snapshot
TickerWorth does not publish a DCF fair value for Nanobiotix S.A. (NBTX); the reason is set out below. What its filings and market data do show is below. The snapshot also sets out its trading multiples against 5 peers. Snapshot as of Oct 19, 2026.
Model by Miraaj Patel · generated from public market data · Updated Oct 19, 2026 · How these pages are made
Why is there no fair value for NBTX?
We do not publish a fair value for Nanobiotix S.A.. What we can say from its filings and market data is below.
What is NBTX's TickerWorth Score?
Scores lower than almost every company we compare it with
Compared with Healthcare companies in US
Its strongest point: a profitable, high-quality business. Its weakest: looks expensive on the numbers.
- Value · 6 of 100
Cheaper than 6% of Healthcare companies in US
- Price vs worth · 0 of 100
- Quality · 54 of 100
More profitable than 54% of Healthcare companies in US
- Financial health · 40 of 100
Financially stronger than 40% of Healthcare companies in US
- Growth · 0 of 100
Growing faster than almost none of the Healthcare companies in US
- Momentum · 30 of 100
Outperformed 30% of Healthcare companies in US over the past year
Confidence: Medium confidence · Scored
Get the Undervalued Company of the Week.
- Price
- $20.92
- Market cap
- $1,
065, 239, 040 - 52-week high
- $57.14
- 52-week low
- $14.78
- Currency
- USD
- Exchange
- NasdaqGS
Snapshot of Oct 19, 2026, quote time not published · Prices are delayed.
What we can say
We don't publish a discounted-cash-flow fair value for Nanobiotix S.A. (NBTX) because the free data sources we rely on don't expose the multi-year financials a DCF needs — common for small or thinly-covered listings. Rather than invent numbers, this page shows an honest snapshot of what the public data does support: the current price and size, any relative valuation multiples that exist, a book-value view, and a price-based read. Treat it as a descriptive starting point, not a valuation and not investment advice.
Read the full reasoning
On the numbers we do have, NBTX trades at a recent price of $20.92, a market capitalisation of about $1,065,239,040, sitting 14% of the way up its 52-week range ($14.78–$57.14), on the NasdaqGS.
The standard alternative to a DCF is relative valuation — comparing NBTX's trading multiples against a sector benchmark. Here that gives P/S of 92.6× (richer than the peer median of 6.2×). A cheaper multiple than peers can flag a discount or a market that expects weaker growth; it is a comparison, not a recommendation.
Finally, a price-based read — explicitly not a valuation. NBTX is in a mixed trend, trading -63.4% from its 52-week high. Over the past year the stock is -13.1%. Moving-average trend and 52-week position describe where the stock has traded; they say nothing about what it is worth.
NBTX vs peers
Sector benchmark (bellwethers, not direct competitors).
| Multiple | NBTX | Peer median | Read |
|---|---|---|---|
| P/S | 92.6× | 6.2× | richer than |
What does Nanobiotix S.A. do?
What does it do?
Nanobiotix S.A. operates as a clinical-stage biotechnology that focuses on developing product candidates for the treatment of cancer and other unmet medical needs. It operates in the Biotechnology industry (Healthcare sector), headquartered in France. The company employs roughly 98 people.
How does it make money?
The business turns $12M in annual revenue into profit. Out of every $100 of sales, about $0 is left as operating profit (operating margin of -322.9%), after a 100% gross margin on the products/services it sells. After all costs, taxes and interest, 0.0% of revenue becomes bottom-line net profit.
Is it financially healthy?
Financially it looks solid: can just cover its short-term bills (1.4× current ratio), and is currently lossmaking.
NBTX insider trading
We have no recent SEC Form 4 insider filings on file for Nanobiotix S.A.. Form 4 covers US-listed companies only.
Companies we do put a number on
Not investment advice. TickerWorth Score is a model output.
A descriptive, available-data snapshot and relative comparison — NOT a DCF, NOT a price target, and NOT investment advice. TickerWorth is not a licensed investment adviser, and these figures are estimates from public market data that can be wrong, stale or incomplete.